# Tarsus Pharmaceuticals, Inc.

Summary updated: 2026-10-02T13:59:10.862251Z
Canonical: https://finbar.com/research/companies/tarsus-pharmaceuticals-inc

## Overview

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics, starting with eye care. Its marketed product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is approved in the United States to treat Demodex blepharitis; its pipeline also includes investigational programs in ocular rosacea and infectious disease prevention. [1](https://app.finbar.com/go?id=P147596764)[2](https://app.finbar.com/go?id=P147597220) The company’s stated mission is “Serving patient needs is our passion; delivering revolutionary treatments is our mission.” [3](https://tarsusrx.com/our-story/)

Tarsus has a U.S.-centered commercial presence and announced a Greater China development and commercialization partnership for TP-03. [4](https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china) For scale, it reported $335.966 million in total revenue for the six months ended June 30, 2026, and 370 full-time employees as of December 31, 2025. [5](https://app.finbar.com/go?id=T16891482)[6](https://app.finbar.com/go?id=P4277214)
[1](https://app.finbar.com/go?id=P147596764)[2](https://app.finbar.com/go?id=P147597220)[3](https://tarsusrx.com/our-story/)[4](https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china)[5](https://app.finbar.com/go?id=T16891482)[6](https://app.finbar.com/go?id=P4277214)[3](https://tarsusrx.com/our-story/)[4](https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china)

## Products & services

Tarsus Pharmaceuticals’ marketed product is XDEMVY® (lotilaner ophthalmic solution) 0.25%, an FDA-approved treatment for Demodex blepharitis. Lotilaner is designed to paralyze and eradicate mites by inhibiting parasite-specific GABA-Cl channels. [7](https://app.finbar.com/go?id=P10022446)[8](https://app.finbar.com/go?id=P22352579) XDEMVY was the company’s only marketed product in the reviewed disclosures. [9](https://app.finbar.com/go?id=P147596968)

Its investigational pipeline includes TP-04, a lotilaner-based sterile aqueous ophthalmic gel being studied for ocular rosacea, and TP-05, an oral lotilaner tablet being developed for Lyme disease prophylaxis and community malaria reduction. Both programs were in Phase 2, according to the company’s 2026 second-quarter filing. [10](https://app.finbar.com/go?id=P147596784)[11](https://app.finbar.com/go?id=P147596768)[12](https://app.finbar.com/go?id=P147596767)[13](https://app.finbar.com/go?id=P147596769) The company also acquired IRX-101 in July 2026: a stable aqueous chlorine dioxide solution under development as an ocular antiseptic intended to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. [14](https://app.finbar.com/go?id=P147596770)[15](https://app.finbar.com/go?id=P147596796)

Net product sales were $319.299 million in the first half of 2026, about 95% of total revenue of $335.966 million; the filing identifies XDEMVY as the company’s only marketed product. [5](https://app.finbar.com/go?id=T16891482)[9](https://app.finbar.com/go?id=P147596968) The reviewed disclosures do not describe separate service offerings.
[7](https://app.finbar.com/go?id=P10022446)[8](https://app.finbar.com/go?id=P22352579)[9](https://app.finbar.com/go?id=P147596968)[10](https://app.finbar.com/go?id=P147596784)[11](https://app.finbar.com/go?id=P147596768)[12](https://app.finbar.com/go?id=P147596767)[13](https://app.finbar.com/go?id=P147596769)[14](https://app.finbar.com/go?id=P147596770)[15](https://app.finbar.com/go?id=P147596796)[5](https://app.finbar.com/go?id=T16891482)

## Geographic presence

Tarsus Pharmaceuticals is headquartered in Irvine, California; its principal executive office is listed at 17700 Laguna Canyon Road, Floor 4, Irvine, California 92618. The company relocated its headquarters in April 2026. [16](https://app.finbar.com/go?id=T16891475)[17](https://app.finbar.com/go?id=P147596522) Its commercial product XDEMVY is sold in the United States. The company reports product sales without a country or regional breakdown, so geographic revenue percentages are not available. [18](https://app.finbar.com/go?id=P28293718)[19](https://app.finbar.com/go?id=P147596294)[20](https://app.finbar.com/go?id=T16891503)

Tarsus licensed TP-03 rights in China to GrandPharma; China is therefore a partner territory, not evidence of direct Tarsus sales. GrandPharma received approval in mainland China in March 2026, triggering a milestone payment to Tarsus. The company has also described exploring development and commercialization opportunities in Europe and Japan, but these are not identified as current sales markets. [21](https://app.finbar.com/go?id=P14679534)[22](https://app.finbar.com/go?id=P147596670)[23](https://app.finbar.com/go?id=P147596858) Tarsus does not operate its own manufacturing facilities and relies on third parties for commercial and clinical/preclinical manufacturing. [24](https://app.finbar.com/go?id=P110321017) No geographic breakdown of employees is disclosed in the reviewed filings.
[16](https://app.finbar.com/go?id=T16891475)[17](https://app.finbar.com/go?id=P147596522)[18](https://app.finbar.com/go?id=P28293718)[19](https://app.finbar.com/go?id=P147596294)[20](https://app.finbar.com/go?id=T16891503)[21](https://app.finbar.com/go?id=P14679534)[22](https://app.finbar.com/go?id=P147596670)[23](https://app.finbar.com/go?id=P147596858)[24](https://app.finbar.com/go?id=P110321017)

## Business segments

Tarsus Pharmaceuticals reports one operating and reportable segment, **therapeutics**, and manages its business on an aggregated basis rather than reporting separate commercial or research-and-development segments. The segment’s activities primarily include U.S. sales of XDEMVY through specialty pharmacies and distributors, as well as license and collaboration revenue from its China out-license. It therefore represents approximately **100% of reported segment revenue**. [25](https://app.finbar.com/go?id=P147596587)

The single-segment structure is consistent with the company’s 2024 reporting. [26](https://app.finbar.com/go?id=P88559405)
[25](https://app.finbar.com/go?id=P147596587)[26](https://app.finbar.com/go?id=P88559405)

## Company history

Tarsus Pharmaceuticals was founded in November 2016 by Bobak (“Bobby”) Azamian and Michael Ackermann. Azamian became president and chief executive officer in September 2018. [18](https://app.finbar.com/go?id=P28293718)[27](https://app.finbar.com/go?id=P57760945) The company completed its initial public offering on October 20, 2020, selling shares at $16 each. [28](https://app.finbar.com/go?id=P177625372)

A major development in Tarsus’s history was its clinical program for TP-03, later named XDEMVY: the drug met primary and secondary endpoints in the Saturn-1 Phase 2b/3 trial in June 2021, and in the Saturn-2 Phase 3 trial in 2022. [29](https://app.finbar.com/go?id=P173613221)[30](https://app.finbar.com/go?id=P15803685) The FDA accepted the company’s new drug application in November 2022 and approved XDEMVY for Demodex blepharitis in July 2023; Tarsus launched the product the following month. [31](https://app.finbar.com/go?id=P111610095)[32](https://app.finbar.com/go?id=P75988479)

In 2026, Tarsus expanded beyond its existing portfolio through acquisitions. It completed the acquisition of iRenix Medical, adding the investigational retina asset IRX-101, and acquired Alkeus Pharmaceuticals, gaining worldwide rights to investigational ALK-001. [33](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/)[34](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus)
[18](https://app.finbar.com/go?id=P28293718)[27](https://app.finbar.com/go?id=P57760945)[28](https://app.finbar.com/go?id=P177625372)[29](https://app.finbar.com/go?id=P173613221)[30](https://app.finbar.com/go?id=P15803685)[31](https://app.finbar.com/go?id=P111610095)[32](https://app.finbar.com/go?id=P75988479)[33](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/)[34](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus)[33](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/)[34](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus)

## Sources

1. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596764)
2. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147597220)
3. [tarsusrx.com](https://tarsusrx.com/our-story/)
4. [ir.tarsusrx.com](https://ir.tarsusrx.com/news-releases/news-release-details/tp-03-lotilaner-ophthalmic-solution-025-now-approved-china)
5. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16891482)
6. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P4277214)
7. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P10022446)
8. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22352579)
9. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596968)
10. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596784)
11. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596768)
12. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596767)
13. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596769)
14. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596770)
15. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596796)
16. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16891475)
17. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596522)
18. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P28293718)
19. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596294)
20. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16891503)
21. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P14679534)
22. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596670)
23. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596858)
24. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P110321017)
25. [Tarsus Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147596587)
26. [Tarsus Pharmaceuticals, Inc. — Full financial report (2024 Y)](https://app.finbar.com/go?id=P88559405)
27. [Tarsus Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P57760945)
28. [Tarsus Pharmaceuticals, Inc. — Full financial report (2020 Y)](https://app.finbar.com/go?id=P177625372)
29. [Tarsus Pharmaceuticals, Inc. — Full financial report (2021 Q 2)](https://app.finbar.com/go?id=P173613221)
30. [Tarsus Pharmaceuticals, Inc. — Full financial report (2022 Q 2)](https://app.finbar.com/go?id=P15803685)
31. [Tarsus Pharmaceuticals, Inc. — Full financial report (2022 Q 3)](https://app.finbar.com/go?id=P111610095)
32. [Tarsus Pharmaceuticals, Inc. — Full financial report (2023 Q 3)](https://app.finbar.com/go?id=P75988479)
33. [ir.tarsusrx.com](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-advances-eye-care-leadership-strategy-acquisition-irenix/)
34. [ir.tarsusrx.com](https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-completes-acquisition-alkeus)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.